Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis

Salinas, Ingrid Parra; Flores, Valle Recasens; Montañés, María Angeles Rodríguez; García‐Erce, José Antonio

doi:10.1016/j.medcle.2018.12.022

Cited by 7 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, the complication rate of RCDs has been shown to be as low as 7%, and the complications are usually benign (e.g., mild hypocalcemia from the citrate anticoagulant) [ 9 ]. However, IJ line placement usually poses greater risks than RCD itself.…”

Section: Discussionmentioning

confidence: 99%

Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis

Machhi

Cunningham

Hennrick

et al. 2022

Case Reports in Hematology

View full text Add to dashboard Cite

We report a patient with hereditary erythrocytosis who underwent a therapeutic phlebotomy and had a post-phlebotomy hematocrit that was higher than the pre-phlebotomy hematocrit. We could not discern a reason for this hematocrit increase after phlebotomy. Instead of performing another phlebotomy, we performed an automated red cell depletion via an apheresis instrument. This procedure is essentially a red cell exchange, but 5% albumin is used as the replacement fluid instead of red blood cells. The patient’s hematocrit decreased from 80% to 39% after three consecutive daily red cell depletion procedures. We share our experience to report the unusual finding of a patient’s hematocrit that increased with phlebotomy and to raise awareness of the red cell depletion procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis

Machhi

Cunningham

Hennrick

et al. 2022

Case Reports in Hematology

View full text Add to dashboard Cite

show abstract

“…Las flebotomías pueden aliviar los síntomas debidos a la hiperviscosidad, sin embargo, se ha demostrado que la eritrocitaféresis es más efectiva comparada con flebotomía, con disminución del hematocrito en menos tiempo, logrando respuestas en el 87% en PV y el 50% en eritrocitosis secundaria 10 .…”

Section: Manejo De Otros Síntomasunclassified

“…Raúl Martínez-Castro 1 , Gilberto Barranco-Lampón 2,3 , Luara Arana-Luna 4 , José L. Álvarez-Vera 4 , Flavio Rojas-Castillejos 5 , Rosalinda Peñaloza-Ramírez 6 , Adrián A. Carballo-Zarate 7 , Irma Olarte-Carrillo 1,8 , Jaime Israel-García Minamy 4 , Javier López-Salazar 4 , Juan J. Navarrete 9 , Arturo Espinosa-Partida 10 , Yanet Ventura-Enríquez 11,12…”

Section: Control De Los Síntomasunclassified

Control de los síntomas

Martínez-Castro,

Barranco-Lampón,

Arana-Luna

et al. 2024

GMM

View full text Add to dashboard Cite

“…Polycythemia Vera include splenomegaly, granulocytosis, thrombocytosis and a point mutation in the tyrosine kinase JAK2 gene. The erythrocytosis refers to the myeloproliferative disorder PoV, in which an abnormal hematopoietic stem cell clone autonomously overproduces red cells to isolated red cell overproduction due to a congenital erythropoietic or hemoglobin defect, chronic hypoxemia related to a respiratory or cardiac disorder, ectopic EPO production (e.g., from renal cell carcinoma, uterine leiomyoma), or EPO augmentation (e.g., post-renal transplantation) and to erythrocytosis in the absence of a primary disorder or features of PoV (5,69).…”

Section: Erythrocytosis and Polycythemia Vera (Pov)mentioning

confidence: 99%

Therapeutic Apheresis, Immunosuppression and Human Monoclonal Anti-bodies in Hematologic diseases most with im-munologic origin

Bambauer

Schiel²,

Salgado³

2022

MRAJ

View full text Add to dashboard Cite

Therapeutic plasma exchange with hollow fiber modules has been used in different severe diseases for more than 45 years. Updated information on molecular biology and immunology of different diseases, the authors discuss in relation to the rationale for apheresis therapy and its place in combination with other modern therapies such as immunosuppressive drugs, cytotoxic agents, and/or human monoclonal antibodies, With the introduction of novel and effective biologic agents, therapeutic apheresis is indicated in severe cases, such as in rapid progression despite immunosuppressive therapy and/or biologic agents. In mild forms of immunologic diseases, treatment with immunosuppressive therapies and/or biologic agents seems to be sufficient. The prognosis of hematologic diseases has improved in recent years, due in part to very aggressive therapy schemes. For the hematologic diseases, especially diseases with an immunologic origin, such as various anemias, erythrocytosis, theombocytopenia, hyperleukocytosis and coagulation inhibitors that can be treated with therapeutic apheresis, the guidelines of the Apheresis Application Committee of the American Society for Apheresis are cited. Therapeutic apheresis has been shown to effectively remove the toxins, autoantibodies, and other substances from blood and lead to rapid clinical improvement. Therapeutic plasma exchange or immunoadsorption aimed at the causative antibodies can be used in diseases caused by antibodies or immune complexes. Adjuvant drug therapies are different for different diseases and are typically individualized in type, dose and duration of use. Therapeutic apheresis can safely be performed in all severe ill patients and is most combined with an immunosuppression therapy. Human monoclonal antibodies are more introduced in hematologic diseases in recent years.

show abstract

Therapeutic erythroapheresis: Experience in patients with polycythemia vera and secondary erythrocytosis

Cited by 7 publications

References 3 publications

Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis

Unexplained Hematocrit Increase after Therapeutic Phlebotomy in a Patient with Marked Erythrocytosis

Control de los síntomas

Therapeutic Apheresis, Immunosuppression and Human Monoclonal Anti-bodies in Hematologic diseases most with im-munologic origin

Contact Info

Product

Resources

About